Show simple item record

dc.contributor.authorHowell, Matthew
dc.contributor.authorLee, Rebecca J
dc.contributor.authorBowyer, Samantha
dc.contributor.authorFusi, Alberto
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2015-04-16T15:14:00Zen
dc.date.available2015-04-16T15:14:00Zen
dc.date.issued2015-05en
dc.identifier.citationOptimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. 2015, 88 (2):117-123 Lung Canceren
dc.identifier.issn1872-8332en
dc.identifier.pmid25776466en
dc.identifier.doi10.1016/j.lungcan.2015.02.007en
dc.identifier.urihttp://hdl.handle.net/10541/550236en
dc.description.abstractAntibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en
dc.titleOptimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BXen
dc.identifier.journalLung Canceren
html.description.abstractAntibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.


Files in this item

This item appears in the following Collection(s)

Show simple item record